FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form of 2-ethyl-6-methyl-3-oxypyridine succinate which is stable during storage and a synthesis method thereof. Synthesis is carried out in water with molar ratio 2-ethyl-6-methyl-3-oxypyridine: succinic acid: water equal to (1:1.055-1.066:10-12) and the end product is extracted at temperature from 0 to +5°C.
EFFECT: stability of the obtained product during storage, absence of toxic impurities, method avoids use of toxic and inflammable organic solvents, which improves working conditions and prevents contamination of the environment and the working area.
7 cl, 21 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR INJECTIONS AND METHOD FOR ITS OBTAINING | 2012 |
|
RU2491054C1 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION OF 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE-2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE DISUCCINATE COMPLEX, HAVING ANTIHYPOXIC, ANTIOXIDANT AND ADAPTOGENIC ACTION | 2013 |
|
RU2527347C1 |
| 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE DICHLOROACETATE, ITS STABLE CRYSTALLINE FORM AND METHOD OF OBTAINING THEREOF | 2013 |
|
RU2540070C1 |
| ALICYCLIC COMPOUNDS, A METHOD OF THEIR SYNTHESIS, A PHARMACEUTICAL COMPOSITION SHOWING ANTI-INFLAMMATORY ACTIVITY AND A METHOD OF TREATMENT OF PATIENTS WITH INFLAMMATION | 1994 |
|
RU2130011C1 |
